Phase 2 Liver Cancer Trial, Recruiting NCT02215889 Sponsor: Oslo University Hospital Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT02215889
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) confirmed by a tissue biopsy.
  • People whose cancer has spread to the liver in a way that cannot be removed by surgery.
  • People whose scans (PET/CT) taken within 4 weeks before the transplant team meeting show no signs of cancer spread outside the liver — although having 1 to 3 small removable spots on the lungs (all smaller than 15mm) may still be acceptable.
  • People whose CT scans of the chest, abdomen, and pelvis taken within 4 weeks before the transplant team meeting show no signs of cancer spread outside the liver — again, 1 to 3 small removable lung spots may still be acceptable.
  • People with rectal cancer who have had an MRI of the pelvis within 4 weeks before the transplant team meeting showing no sign of the cancer returning in the pelvis.
  • People who have had a bowel examination (colonoscopy or CT scan of the bowel) within 12 months before the transplant team meeting showing no sign of the cancer returning locally.
  • People who are in good general health and able to carry out everyday activities with little or no limitation (confirmed with trial site).
  • People whose blood test results meet required levels for red blood cells, white blood cells, platelets, liver function, kidney function, and protein levels (confirm specific values with trial site).
  • People who have given written consent and are willing and able to attend treatment and follow-up appointments as required.
  • People who have already received at least 8 weeks of chemotherapy.

Who may not be able to join:

  • People who have lost more than 10% of their body weight in the past 6 months.
  • People with a Body Mass Index (BMI) over 30 (a commonly used measure of body weight relative to height).
  • People who have previously been diagnosed with cancer that has spread to the bones or brain/nervous system.
  • People who have previously been diagnosed with breast cancer or melanoma (a type of skin cancer).
  • People who have had surgery to remove part of their bowel cancer for comfort or symptom relief rather than with the intent to cure.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 23026600

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 June 2014
Est. completion
1 June 2025

Where this trial is recruiting

🇳🇴 Norway

Primary endpoints

Percent of transplanted patients receiving second stage hepatectomy within 4 weeks of segment 2/3 transplantation.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov